Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

R.J. Mairs, C.L. Wideman, W.J. Angerson, T.L. Whateley, M.S. Reza, J.R. Reeves, L.M. Robertson, A. Neshasteh-Riz

    Research output: Contribution to journalArticlepeer-review

    26 Citations (Scopus)


    As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.
    Original languageEnglish
    Pages (from-to)74-80
    Number of pages6
    JournalBritish Journal of Cancer
    Issue number1
    Publication statusPublished - Jan 2000


    • radioiododeoxyuridine
    • glioma
    • intracerebral therapy
    • rat
    • sustained release
    • Hodgkin's disease
    • lymphoma
    • cost-effectiveness
    • high dose chemotherapy
    • transplantation

    Cite this